Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Nathan Martin, PhD, Ethan G. Thompson, PhD, Will Brown, MS, Olivia Finney, PhD, Julie Rytlewski, PhD, Yue Jiang, PhD, Dipen Sangurdekar, PhD, Julie Wang, PharmD, PhD, Hans Bitter, PhD, Ronald J. Hause, Jr., PhD, Timothy B. Campbell, MD PhD, Kristen Hege, MD, Shari Kaiser, PhD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-134378

Published: 2020

Journal Articles

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-142426

Published: 2020

Journal Articles

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Julie Rytlewski, PhD, Deepu Madduri, MD, Jaymes Fuller, PhD, Timothy B. Campbell, MD PhD, Afshin Mashadi-Hossein, MSc, Ethan G. Thompson, PhD, Yue Jiang, PhD, Nathan Martin, PhD, Dipen Sangurdekar, PhD, Olivia Finney, PhD, Hans Bitter, PhD, Amit Agarwal, MD PhD, Shari Kaiser, PhD, Kristen Hege, MD, Ronald J. Hause, Jr., PhD

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134369

Published: 2020

Journal Articles

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Mehmet K. Samur, PhD, Mariateresa Fulciniti, PhD, Anil Aktas-Samur, PhD, Abdul Hamid Bazarbachi, MD, Yu-Tzu Tai, PhD, Timothy B. Campbell, MD PhD, Fabio Petrocca, MD, Kristen Hege, MD, Shari Kaiser, PhD, Kenneth Anderson, MD, Nikhil C. Munshi, MD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-139040

Published: 2020

Journal Articles

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Ethan G. Thompson, PhD, Yue Jiang, PhD, Timothy B. Campbell, MD PhD, Jaymes Fuller, PhD, Shari Kaiser, PhD, Afshin Mashadi-Hossein, MSc, Julie Rytlewski, PhD, Nathan Martin, PhD, Olivia Finney, PhD, Katja Kleinsteuber, PhD, Eric Alonzo, PhD, Chetanya Pandya, PhD, Amit Agarwal, MD PhD, Kristen Hege, Noopur S. Raje, MD, Nikhil C. Munshi, MD, Ronald J. Hause, PhD

Blood (2019) 134 (Supplement_1): 4328.

https://doi.org/10.1182/blood-2019-124998

Published: 2019

NARROW

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Idecabtagene Vicleucel (ide-cel, bb2121) Responses Are Characterized By Early and Temporally Consistent Activation and Expansion of CAR T Cells with a T Effector Phenotype

Molecular and Phenotypic Profiling of Drug Product and Post-Infusion Samples from CRB-402, an Ongoing: Phase I Clinical Study of bb21217 a BCMA-Directed CAR T Cell Therapy

Effects of Prior Alkylating Therapies on Preinfusion Patient Characteristics and Starting Material for CAR T Cell Product Manufacturing in Late-Line Multiple Myeloma

Biallelic Loss of BCMA Triggers Resistance to Anti-BCMA CAR T Cell Therapy in Multiple Myeloma

Markers of Initial and Long-Term Responses to Idecabtagene Vicleucel (Ide-Cel; bb2121) in the CRB-401 Study in Relapsed/Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only